Skip to content
    Astellas Venture Management logo

    Astellas Venture Management

    Menlo Park, California, United StatesFounded 1999
    www.astellasventure.com/home
    Biotech & Life Sciences

    Astellas Venture Management (AVM) is the wholly-owned corporate venture capital arm of Astellas Pharma Inc., focused on equity investments in early-stage, pre-clinical biotechnology companies advancing therapeutic programs and platform technologies for drug discovery.

    58% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (2 deals in the last 12 months vs 3 prior). Their most common stage is series-b (43% of deals). Average disclosed round size is $45.1M (across 40 rounds with reported amounts).

    Find people at Astellas Venture Management on Goldilocks AI

    Portfolio

    35

    Fund Size

    —

    Top Stage

    Series B

    Last 12 Mo

    2

    Team

    CH

    Chihiro Hosoya, MSC, MBA

    Investment Director

    KI

    Kazunori Inabe

    Associate Investment Director

    HU

    Hiroyuki Usuda

    Investment Lead

    SK

    Satoshi Konagai

    Investment Lead

    SI

    Sorato Ikeda

    Senior Investment Manager

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    53 investments
    CompanyRoundAmountDate
    Syntax logoSyntaxSeries A$14.4MJun 2026
    Sidewinder logoSidewinderSeries B$137MApr 2026
    SSidewinder TherapeuticsSeries B$137MJan 2026
    Sidewinder logoSidewinderSeries B$137MJan 2026
    RRestore Vision Inc.Series A—Jan 2026
    Somite logoSomiteSeries A$47MMay 2025
    Solu logoSoluSeries A$41MApr 2025
    SSolu TherapeuticsSeries A$41MApr 2025
    NeoPhore logoNeoPhoreSeries B—Feb 2024
    Shinobi Therapeutics logoShinobi TherapeuticsSeries A$51MJan 2023
    DEM BioPharma logoDEM BioPharmaUnknown$70MJun 2022
    Carbon Biosciences logoCarbon BiosciencesSeries A$38MJun 2022
    Turn Biotechnologies logoTurn BiotechnologiesUnknown—Apr 2022
    PhoreMost logoPhoreMostSeries B$46MMar 2021
    NeoPhore logoNeoPhoreSeries B—Jan 2021
    PhoreMost logoPhoreMostSeries B$12MJan 2021
    MMogrifySeries A$33MJan 2021
    Orna Therapeutics logoOrna TherapeuticsSeries A$80MJan 2021
    CCatamaran BioSeries A$42MJan 2020
    Heartseed logoHeartseedSeries B$26MNov 2019
    CCODA Biotherapeutics, IncSeries A$34MNov 2019
    Heartseed logoHeartseedSeries B$26MJan 2019
    Oncorus logoOncorusSeries B$79.5MJan 2019
    IIota BiosciencesSeries A$15MMay 2018
    IIota BiosciencesSeries A$15MJan 2018
    Page 1 of 3

    Top Co-Investors

    Longwood Fund9 shared
    MPM Capital9 shared
    Novartis Venture Fund8 shared
    Alexandria Venture Investments7 shared
    Amgen Ventures7 shared
    Abingworth LLP6 shared
    InterWest Partners5 shared
    DCVC4 shared
    OrbiMed4 shared
    JIC Venture Growth Investments4 shared
    Lightstone Ventures4 shared
    Osage University Partners3 shared
    Pappas Capital3 shared
    Alta Partners3 shared
    Life Sciences at Goldman Sachs Alternatives3 shared
    Samsara BioCapital3 shared
    Frazier Life Sciences3 shared
    3B Future Health Fund3 shared
    Ajinomoto Group Ventures3 shared
    Parkwalk Advisors3 shared

    Last updated: 27 September 2026